Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Cytomegalovirus Infections | 9 | 2019 | 667 | 4.05 | Why? |
| Cytomegalovirus | 7 | 2019 | 600 | 3.08 | Why? |
| Hematopoietic Stem Cell Transplantation | 8 | 2018 | 2426 | 1.49 | Why? |
| Organ Transplantation | 9 | 2019 | 2616 | 1.46 | Why? |
| Graft Rejection | 5 | 2021 | 1766 | 1.06 | Why? |
| Quinazolines | 3 | 2018 | 126 | 1.01 | Why? |
| Acetates | 3 | 2018 | 123 | 0.98 | Why? |
| Opportunistic Infections | 3 | 2018 | 602 | 0.97 | Why? |
| Foscarnet | 2 | 2018 | 13 | 0.93 | Why? |
| Ganciclovir | 2 | 2019 | 97 | 0.90 | Why? |
| Mycobacterium tuberculosis | 3 | 2018 | 1164 | 0.84 | Why? |
| Home Infusion Therapy | 1 | 2021 | 128 | 0.82 | Why? |
| Facial Transplantation | 1 | 2019 | 5 | 0.79 | Why? |
| Roseolovirus Infections | 2 | 2017 | 131 | 0.78 | Why? |
| Arthroplasty, Replacement | 1 | 2019 | 47 | 0.76 | Why? |
| Health Information Exchange | 1 | 2020 | 151 | 0.73 | Why? |
| Hepatic Duct, Common | 1 | 2017 | 2 | 0.72 | Why? |
| Tuberculosis | 3 | 2018 | 2895 | 0.70 | Why? |
| Rhodococcus | 1 | 2017 | 5 | 0.70 | Why? |
| Actinomycetales Infections | 1 | 2017 | 10 | 0.69 | Why? |
| Klatskin Tumor | 1 | 2017 | 25 | 0.68 | Why? |
| Immunocompetence | 1 | 2019 | 280 | 0.68 | Why? |
| Lung Transplantation | 3 | 2019 | 1554 | 0.67 | Why? |
| Biliary Tract Surgical Procedures | 1 | 2017 | 32 | 0.67 | Why? |
| Herpesvirus 8, Human | 1 | 2017 | 97 | 0.64 | Why? |
| Allografts | 2 | 2021 | 761 | 0.61 | Why? |
| Antibiotic Prophylaxis | 1 | 2019 | 399 | 0.60 | Why? |
| Clostridium Infections | 3 | 2018 | 595 | 0.60 | Why? |
| Cholangitis, Sclerosing | 1 | 2017 | 106 | 0.60 | Why? |
| Prosthesis-Related Infections | 1 | 2019 | 302 | 0.59 | Why? |
| Liver Transplantation | 4 | 2021 | 2864 | 0.56 | Why? |
| Bile Duct Neoplasms | 1 | 2017 | 172 | 0.55 | Why? |
| Preventive Health Services | 1 | 2020 | 501 | 0.55 | Why? |
| Postoperative Complications | 3 | 2017 | 5861 | 0.54 | Why? |
| Mycoses | 2 | 2019 | 589 | 0.53 | Why? |
| Antibodies, Monoclonal, Humanized | 5 | 2021 | 9335 | 0.50 | Why? |
| End Stage Liver Disease | 1 | 2017 | 418 | 0.47 | Why? |
| Antiviral Agents | 11 | 2021 | 41703 | 0.46 | Why? |
| Lymphocyte Subsets | 1 | 2019 | 987 | 0.46 | Why? |
| Living Donors | 1 | 2017 | 652 | 0.46 | Why? |
| Hematologic Diseases | 1 | 2018 | 614 | 0.45 | Why? |
| Critical Pathways | 1 | 2021 | 1587 | 0.42 | Why? |
| Viremia | 1 | 2018 | 1020 | 0.42 | Why? |
| Antifungal Agents | 2 | 2019 | 1828 | 0.40 | Why? |
| Renal Replacement Therapy | 1 | 2018 | 1530 | 0.37 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2017 | 2309 | 0.37 | Why? |
| Anti-Infective Agents | 1 | 2019 | 1766 | 0.34 | Why? |
| Guidelines as Topic | 1 | 2020 | 2844 | 0.33 | Why? |
| Heart Transplantation | 1 | 2017 | 1293 | 0.32 | Why? |
| Health Status | 1 | 2020 | 3259 | 0.32 | Why? |
| Immunocompromised Host | 5 | 2018 | 5150 | 0.30 | Why? |
| Transplantation, Homologous | 2 | 2018 | 757 | 0.29 | Why? |
| Herpesvirus 6, Human | 2 | 2017 | 162 | 0.29 | Why? |
| Antibodies, Monoclonal | 2 | 2021 | 8041 | 0.28 | Why? |
| Databases, Factual | 1 | 2018 | 6248 | 0.25 | Why? |
| Education, Medical | 1 | 2020 | 2461 | 0.25 | Why? |
| Risk Factors | 13 | 2021 | 71621 | 0.25 | Why? |
| Hospitalization | 5 | 2021 | 54280 | 0.23 | Why? |
| Communicable Diseases | 1 | 2017 | 2148 | 0.23 | Why? |
| Urinary Tract Infections | 2 | 2018 | 534 | 0.23 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2019 | 5837 | 0.23 | Why? |
| Drug Resistance, Viral | 2 | 2018 | 1083 | 0.23 | Why? |
| Meta-Analysis as Topic | 2 | 2018 | 1289 | 0.22 | Why? |
| Humans | 43 | 2021 | 930598 | 0.21 | Why? |
| Survival Rate | 3 | 2021 | 9206 | 0.20 | Why? |
| Follow-Up Studies | 5 | 2020 | 17020 | 0.20 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.19 | Why? |
| Premedication | 1 | 2018 | 40 | 0.19 | Why? |
| Antidiarrheals | 1 | 2018 | 13 | 0.18 | Why? |
| Tissue Donors | 2 | 2018 | 1679 | 0.18 | Why? |
| Anastomosis, Roux-en-Y | 1 | 2017 | 24 | 0.17 | Why? |
| Mutation | 1 | 2018 | 12376 | 0.17 | Why? |
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 290 | 0.17 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 11367 | 0.17 | Why? |
| Organizational Culture | 1 | 2021 | 395 | 0.17 | Why? |
| Liver Failure, Acute | 1 | 2021 | 279 | 0.17 | Why? |
| Kaplan-Meier Estimate | 2 | 2017 | 4260 | 0.17 | Why? |
| Administration, Intravenous | 1 | 2021 | 1115 | 0.17 | Why? |
| Graft Survival | 2 | 2017 | 587 | 0.17 | Why? |
| Bile Ducts | 1 | 2017 | 84 | 0.17 | Why? |
| Efficiency, Organizational | 1 | 2021 | 482 | 0.17 | Why? |
| DNA, Viral | 2 | 2017 | 2521 | 0.16 | Why? |
| Viral Load | 4 | 2018 | 15850 | 0.16 | Why? |
| Transplant Recipients | 3 | 2018 | 4982 | 0.16 | Why? |
| Multimorbidity | 1 | 2021 | 703 | 0.16 | Why? |
| Disease-Free Survival | 1 | 2021 | 1654 | 0.16 | Why? |
| Sarcoma, Kaposi | 1 | 2017 | 97 | 0.16 | Why? |
| Hemofiltration | 1 | 2018 | 155 | 0.15 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2018 | 309 | 0.15 | Why? |
| Fecal Microbiota Transplantation | 2 | 2018 | 372 | 0.15 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.15 | Why? |
| Drug Resistance | 1 | 2018 | 395 | 0.15 | Why? |
| Male | 20 | 2021 | 367725 | 0.14 | Why? |
| Middle Aged | 14 | 2021 | 270681 | 0.14 | Why? |
| Drug Combinations | 2 | 2021 | 3852 | 0.14 | Why? |
| Triazoles | 1 | 2019 | 440 | 0.14 | Why? |
| Immunotherapy | 2 | 2018 | 2421 | 0.14 | Why? |
| Adult | 14 | 2021 | 244371 | 0.14 | Why? |
| Program Development | 1 | 2021 | 1089 | 0.14 | Why? |
| Reoperation | 1 | 2017 | 544 | 0.14 | Why? |
| Prognosis | 4 | 2018 | 32490 | 0.13 | Why? |
| Aged | 14 | 2021 | 215776 | 0.13 | Why? |
| Arthroplasty, Replacement, Knee | 1 | 2019 | 363 | 0.13 | Why? |
| Arthroplasty, Replacement, Hip | 1 | 2019 | 403 | 0.13 | Why? |
| Mobile Health Units | 1 | 2021 | 741 | 0.13 | Why? |
| Intersectoral Collaboration | 1 | 2021 | 1065 | 0.13 | Why? |
| Delivery of Health Care | 1 | 2020 | 15909 | 0.13 | Why? |
| Informed Consent | 1 | 2021 | 890 | 0.13 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.12 | Why? |
| Retrospective Studies | 9 | 2021 | 105322 | 0.12 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.12 | Why? |
| Pandemics | 10 | 2021 | 389249 | 0.12 | Why? |
| Female | 18 | 2021 | 380317 | 0.12 | Why? |
| Recurrence | 2 | 2019 | 3675 | 0.12 | Why? |
| Skilled Nursing Facilities | 1 | 2021 | 1098 | 0.12 | Why? |
| Treatment Outcome | 7 | 2021 | 51732 | 0.11 | Why? |
| Mycobacterium Infections | 1 | 2011 | 72 | 0.11 | Why? |
| Incidence | 3 | 2018 | 25622 | 0.11 | Why? |
| Donor Selection | 1 | 2018 | 804 | 0.11 | Why? |
| Teaching | 1 | 2020 | 1208 | 0.11 | Why? |
| Nontuberculous Mycobacteria | 1 | 2011 | 114 | 0.10 | Why? |
| Adolescent | 7 | 2021 | 86841 | 0.10 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.10 | Why? |
| Travel-Related Illness | 1 | 2018 | 1357 | 0.10 | Why? |
| Clinical Protocols | 1 | 2021 | 2734 | 0.10 | Why? |
| Diarrhea | 2 | 2020 | 2743 | 0.10 | Why? |
| Medication Adherence | 1 | 2019 | 1270 | 0.10 | Why? |
| Ribavirin | 1 | 2016 | 1182 | 0.09 | Why? |
| Young Adult | 5 | 2021 | 93724 | 0.09 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.09 | Why? |
| Respiratory Syncytial Virus Infections | 1 | 2016 | 1234 | 0.08 | Why? |
| Patient Care Team | 1 | 2020 | 3556 | 0.08 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.07 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.07 | Why? |
| Immunosuppressive Agents | 3 | 2018 | 6331 | 0.07 | Why? |
| Immunoglobulins, Intravenous | 1 | 2016 | 2705 | 0.07 | Why? |
| Immunization, Passive | 1 | 2020 | 10067 | 0.07 | Why? |
| Immunologic Factors | 1 | 2020 | 4206 | 0.07 | Why? |
| Aged, 80 and over | 4 | 2021 | 88759 | 0.06 | Why? |
| United States | 2 | 2021 | 46150 | 0.06 | Why? |
| Complement C4b | 1 | 2021 | 57 | 0.06 | Why? |
| Kidney Transplantation | 1 | 2021 | 5397 | 0.05 | Why? |
| Chills | 1 | 2020 | 102 | 0.05 | Why? |
| Staining and Labeling | 1 | 2021 | 169 | 0.05 | Why? |
| Renal Dialysis | 1 | 2018 | 4358 | 0.05 | Why? |
| Biomedical Research | 1 | 2020 | 5270 | 0.05 | Why? |
| Anti-Bacterial Agents | 3 | 2017 | 10083 | 0.05 | Why? |
| Viral Proteins | 1 | 2018 | 7370 | 0.05 | Why? |
| Minnesota | 1 | 2021 | 509 | 0.05 | Why? |
| Capillaries | 1 | 2021 | 257 | 0.05 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2013 | 2984 | 0.05 | Why? |
| Itraconazole | 1 | 2019 | 135 | 0.04 | Why? |
| Case-Control Studies | 1 | 2017 | 17671 | 0.04 | Why? |
| Cytokines | 1 | 2020 | 15010 | 0.04 | Why? |
| Intensive Care Units | 2 | 2021 | 29594 | 0.04 | Why? |
| Voriconazole | 1 | 2019 | 206 | 0.04 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.04 | Why? |
| Child, Preschool | 2 | 2020 | 36283 | 0.04 | Why? |
| Infusions, Intravenous | 1 | 2020 | 1224 | 0.04 | Why? |
| Polymerase Chain Reaction | 2 | 2021 | 6740 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.04 | Why? |
| Dysgeusia | 1 | 2020 | 524 | 0.04 | Why? |
| Invasive Fungal Infections | 1 | 2019 | 274 | 0.04 | Why? |
| Myalgia | 1 | 2020 | 1015 | 0.03 | Why? |
| Cohort Studies | 1 | 2018 | 36005 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Patients | 1 | 2021 | 1167 | 0.03 | Why? |
| Virus Activation | 1 | 2017 | 480 | 0.03 | Why? |
| Biopsy | 1 | 2021 | 2811 | 0.03 | Why? |
| Child | 2 | 2020 | 70012 | 0.03 | Why? |
| Drug Interactions | 1 | 2019 | 1653 | 0.03 | Why? |
| Dose-Response Relationship, Drug | 1 | 2020 | 3776 | 0.03 | Why? |
| Peptide Fragments | 1 | 2021 | 2075 | 0.03 | Why? |
| Debridement | 1 | 2011 | 172 | 0.03 | Why? |
| Oseltamivir | 1 | 2013 | 583 | 0.02 | Why? |
| Graft vs Host Disease | 1 | 2013 | 501 | 0.02 | Why? |
| Respiratory Therapy | 1 | 2016 | 918 | 0.02 | Why? |
| Respiratory Syncytial Virus, Human | 1 | 2016 | 846 | 0.02 | Why? |
| Administration, Oral | 1 | 2016 | 2340 | 0.02 | Why? |
| Microbial Sensitivity Tests | 1 | 2017 | 2886 | 0.02 | Why? |
| Influenza, Human | 1 | 2013 | 10779 | 0.02 | Why? |
| Kidney | 1 | 2021 | 3648 | 0.02 | Why? |
| Data Collection | 1 | 2016 | 1769 | 0.02 | Why? |
| Referral and Consultation | 1 | 2021 | 4816 | 0.02 | Why? |
| Fever | 1 | 2020 | 7795 | 0.02 | Why? |
| Olfaction Disorders | 1 | 2020 | 3704 | 0.01 | Why? |
| Infant, Newborn | 1 | 2020 | 23105 | 0.01 | Why? |
| Infant | 1 | 2020 | 30274 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2018 | 11041 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.01 | Why? |
| Risk Assessment | 1 | 2018 | 25439 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.01 | Why? |
| Cross Infection | 1 | 2013 | 8675 | 0.01 | Why? |
| Infection Control | 1 | 2013 | 23131 | 0.00 | Why? |
Razonable's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(194)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(241)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_